Culver Kirsten E, Szechtman Henry
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada L8N 3Z5.
Horm Behav. 2004 Jan;45(1):23-30. doi: 10.1016/j.yhbeh.2003.07.004.
Repeated administration of the dopamine agonist quinpirole induces behavioral sensitization in rats that is characterized by a four- to eight-fold increase in the amount of locomotion compared to an acute dose of quinpirole, in the absence of any increases in mouthing behavior. The monoamine oxidase (MAO) inhibitor, clorgyline, switches behavioral sensitization to quinpirole from that of locomotion to self-directed mouthing. The mechanism by which clorgyline produces this switch in behavioral sensitization is unknown, but is independent of the known effects of clorgyline, namely, inhibition of MAO, inhibition of striatal dopamine uptake, or stimulation of sigma and I(2) receptors. Because clorgyline also inhibits hypothalamo-pituitary-adrenal (HPA) axis function, and increased HPA activity facilitates the behavioral effects of psychostimulant drugs, the effects of clorgyline on quinpirole sensitization are possibly due to an inhibition of HPA function. Therefore, the present study examined whether HPA activity is required for sensitization to quinpirole, and whether clorgyline exerts its effects on quinpirole sensitization via inhibition of HPA function. Control and hypophysectomized rats were administered clorgyline (1 mg/kg, s.c.) or vehicle 90 min before each injection of quinpirole (0.5 mg/kg x 8, twice weekly) or saline. To assess the level of sensitization reached by control and hypophysectomized rats, test injections of quinpirole (0.0, 0.07, and 0.2 mg/kg) were administered. Chronic quinpirole administration produced equivalent levels of locomotor sensitization in control and hypophysectomized rats. Clorgyline was equally effective in blocking the development of locomotor sensitization in control and hypophysectomized rats, and in sensitizing self-directed mouthing. The present study suggests that (1). HPA function is not necessary for the development of quinpirole sensitization and, (2). clorgyline does not produce its effects on behavioral sensitization to quinpirole via an inhibition of HPA activity. Moreover, the observation that quinpirole sensitization develops normally in the absence of any pituitary endocrine function suggests that pituitary-gonadal and pituitary-thyroid axes activity are also not necessary for quinpirole sensitization to occur.
重复给予多巴胺激动剂喹吡罗可诱导大鼠产生行为敏化,其特征为与急性给予喹吡罗相比,运动行为量增加4至8倍,且口部行为无任何增加。单胺氧化酶(MAO)抑制剂氯吉兰可使对喹吡罗的行为敏化从运动行为转变为自我指向性口部行为。氯吉兰产生这种行为敏化转变的机制尚不清楚,但独立于氯吉兰的已知作用,即抑制MAO、抑制纹状体多巴胺摄取或刺激西格玛和I(2)受体。由于氯吉兰还抑制下丘脑 - 垂体 - 肾上腺(HPA)轴功能,且HPA活性增加会促进精神兴奋药物的行为效应,所以氯吉兰对喹吡罗敏化的影响可能是由于抑制了HPA功能。因此,本研究考察了HPA活性对于喹吡罗敏化是否必要,以及氯吉兰是否通过抑制HPA功能对喹吡罗敏化产生作用。在每次注射喹吡罗(0.5mg/kg×8次,每周两次)或生理盐水前90分钟,给对照大鼠和垂体切除大鼠皮下注射氯吉兰(1mg/kg)或赋形剂。为评估对照大鼠和垂体切除大鼠达到的敏化水平,进行了喹吡罗(0.0、0.07和0.2mg/kg)的测试注射。慢性给予喹吡罗在对照大鼠和垂体切除大鼠中产生了同等程度的运动敏化。氯吉兰在阻断对照大鼠和垂体切除大鼠的运动敏化发展以及使自我指向性口部行为敏化方面同样有效。本研究表明:(1). HPA功能对于喹吡罗敏化的发展并非必要;(2). 氯吉兰并非通过抑制HPA活性对喹吡罗行为敏化产生作用。此外,在不存在任何垂体内分泌功能的情况下喹吡罗敏化仍正常发展这一观察结果表明,垂体 - 性腺轴和垂体 - 甲状腺轴的活性对于喹吡罗敏化的发生也并非必要。